anti-MALAT1 gapmeR

Anti-MALAT1 gapmeR is a 16-mer Locked Nucleic Acid (LNA)-modified antisense oligonucleotide designed to target the long non-coding RNA (lncRNA) Metastasis Associated Lung Adenocarcinoma Transcript 1 (MALAT1). It operates via an RNase H-dependent mechanism to trigger the degradation of MALAT1 transcripts. In the context of multiple myeloma, MALAT1 is frequently overexpressed and contributes to disease progression. Treatment with this gapmer has been shown to down-regulate 20S proteasome β subunits (PSMβ2, PSMβ4, PSMβ5, and PSMβ7) by inhibiting the transcription factors NRF1 and NRF2. This inhibition leads to reduced proteasomal activity, the accumulation of poly-ubiquitylated proteins, induction of endoplasmic reticulum (ER) stress, and subsequent apoptosis in myeloma cells. Preclinical evidence suggests that anti-MALAT1 gapmeRs can inhibit tumor growth in xenograft models and enhance the activity of proteasome inhibitors like bortezomib.

Other names

anti-MALAT1 synthetic oligonucleotideanti-MALAT-1 synthetic oligonucleotideanti-MALAT 1 synthetic oligonucleotideMALAT1 LNA-gapmeRMALAT-1 LNA-gapmeRMALAT 1 LNA-gapmeR